C3 and age-related macular degeneration: A phase 1 trial of NGM621, an immunoglobulin G1 monoclonal antibody with 2-point mutations in the Fc region, in the inhibition of C3 in patients with GA secondary to AMD found this to be a safe and tolerable drug with no obvious impact on newly formed CNV/MNV [46].